Circassia Pharmaceuticals PLC  

(Public, LON:CIR)   Watch this stock  
Find more results for Charles L. Cummings
98.25
+1.10 (1.13%)
Jul 22 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 96.00 - 99.25
52 week 81.05 - 356.00
Open 96.00
Vol / Avg. 0.00/1.16M
Mkt cap 279.90M*
P/E     -
Div/yield     -
EPS -0.20*
Shares 284.89M
Beta     -
Inst. own     -
*GBP

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -276.41% -462.96%
Operating margin -391.95% -614.81%
EBITD margin - -598.15%
Return on average assets -11.06% -14.50%
Return on average equity -13.30% -16.54%
Employees 204 -
CDP Score - -

Address

Northbrook House, Robert Robinson Avenue
OXFORD, OX4 4GA
United Kingdom - Map
+44-1865-405560 (Phone)
+44-1865-784576 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Officers and directors

Francesco Granata M.D. Non-Executive Chairman of the Board
Age: 64
Steven Harris Chief Executive Officer, Executive Director
Age: 48
Julien Cotta Chief Financial Officer, Executive Director
Age: 51
Rod Hafner Senior Vice President - Research & Development, Executive Director
Age: 49
Steve Pawsey Chief Medical Officer
Russell Cummings Non-Executive Director
Age: 50
Cathrin Petty Non-Executive Director
Age: 41
Marvin S. Samson Non-Executive Director
Age: 67
Charles Swingland Non-Executive Director
Age: 62
Tim Corn Non-Executive Independent Director
Age: 63